To the best of our knowledge, this is the most up-to-date systematic review and NMA to comprehensively investigate the impact of individual SGLT2 inhibitors on the clinical outcomes among patients with and without DM, CKD, and HF. The gene discussed is SLC5A2; the disease is chronic kidney disease.